Redeye initiates coverage of medical technology company Bibb Instruments with a fair value of SEK 0.67 per share in the base case, corresponding to upside of approximately 38 percent. This is stated in an analysis. The valuation includes only the Endodrill GI biopsy product, which is now entering the commercialization phase in the US and Europe.Redeye assesses that the next 12-24 months will be important for confirming the product's commercial and clinical potential. Endodrill GI is regulatory-approved in both the US and Europe, but broader use is expected to require larger comparative studies demonstrating clinical and economic benefits.In an optimistic scenario, which also includes Endodrill EBUS for lung biopsies, Redeye sets the value at SEK 1.03 per share. The analysis's valuation range includes an assumed SEK 60 million rights issue during the first quarter of 2028. Redeye expects positive free cash flow in 2030, when sales are expected to reach SEK 75 million.